Nektar Therapeutics (NKTR) vs Palvella Therapeutics, Inc. (PVLA)
Nektar Therapeutics and Palvella Therapeutics, Inc. are both Biotechnology companies. Nektar Therapeutics and Palvella Therapeutics, Inc. are of similar size ($2.1B and $2.1B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 142.9% against −27.2%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −287.8%) and the higher return on invested capital (0.00% vs −40.2%). Across the 16 metrics below, Palvella Therapeutics, Inc. leads on 11 and Nektar Therapeutics on 5.
Valuation
Profitability
| Metric | NKTR | PVLA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (257.80%) | 0.00% | 0.00% |
| Net margin | (287.84%) | 0.00% | 0.00% |
| Free cash flow margin | (428.72%) | 0.00% | 0.00% |
| Return on equity | (35.75%) | (46.63%) | (57.72%) |
| Return on assets | (24.12%) | (37.70%) | (49.22%) |
| Return on invested capital | (40.20%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack